[go: up one dir, main page]

TR200200066T2 - Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri - Google Patents

Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri

Info

Publication number
TR200200066T2
TR200200066T2 TR2002/00066T TR200200066T TR200200066T2 TR 200200066 T2 TR200200066 T2 TR 200200066T2 TR 2002/00066 T TR2002/00066 T TR 2002/00066T TR 200200066 T TR200200066 T TR 200200066T TR 200200066 T2 TR200200066 T2 TR 200200066T2
Authority
TR
Turkey
Prior art keywords
receptor antagonists
migraine
iglur5 receptor
treatment
selective iglur5
Prior art date
Application number
TR2002/00066T
Other languages
English (en)
Inventor
Bleakman David
Suzon Chappell Amy
Ann Filla Sandra
Willis Johnson Kirk
Leslie Ornstein Paul
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR200200066T2 publication Critical patent/TR200200066T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bu bulus, migrenin tedavi edilmesi ya da engellenmesi için bir kullanim temin etmektedir, bu kullanim, bir seçici iGluR5 reseptör antagonistinin etkili bir miktarinin ihtiyaç duyan bir hastaya tatbik edilmesini içermektedir. Bu bulus, bundan baska, seçici iGluR5 reseptör antagonistleri olarak islevli yeni bilesiklerin yanisira bahsedilen seçici iGluR5 reseptör antagonistlerini içeren bilesimler ve formülasyonlari temin etmektedir.
TR2002/00066T 1999-07-06 2000-06-27 Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri TR200200066T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14248599P 1999-07-06 1999-07-06
US15116599P 1999-08-27 1999-08-27

Publications (1)

Publication Number Publication Date
TR200200066T2 true TR200200066T2 (tr) 2002-04-22

Family

ID=26840135

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00066T TR200200066T2 (tr) 1999-07-06 2000-06-27 Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri

Country Status (28)

Country Link
US (4) US6566370B1 (tr)
EP (1) EP1200073B1 (tr)
JP (1) JP4619595B2 (tr)
KR (1) KR20020024300A (tr)
CN (1) CN1230174C (tr)
AR (1) AR029373A1 (tr)
AU (1) AU773304B2 (tr)
BR (1) BR0012175A (tr)
CA (1) CA2378613C (tr)
CZ (1) CZ20014488A3 (tr)
DE (1) DE60032905T2 (tr)
DK (1) DK1200073T3 (tr)
DZ (1) DZ3209A1 (tr)
EA (1) EA004290B1 (tr)
ES (1) ES2278619T3 (tr)
HK (1) HK1047036A1 (tr)
HR (1) HRP20020013A2 (tr)
HU (1) HUP0202253A3 (tr)
IL (1) IL146697A0 (tr)
MX (1) MXPA01012726A (tr)
MY (1) MY133503A (tr)
NO (1) NO20016246L (tr)
NZ (1) NZ515616A (tr)
PE (1) PE20010299A1 (tr)
PT (1) PT1200073E (tr)
SK (1) SK112002A3 (tr)
TR (1) TR200200066T2 (tr)
WO (1) WO2001001972A2 (tr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579886B2 (en) 1999-12-22 2003-06-17 Eli Lilly And Company Selective iglur5 receptor antagonists
EP1351952A2 (en) * 2001-01-05 2003-10-15 Eli Lilly And Company Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
CN100548299C (zh) * 2001-01-05 2009-10-14 伊莱利利公司 兴奋性氨基酸受体拮抗剂
CN1484642A (zh) * 2001-01-05 2004-03-24 兴奋性氨基酸受体拮抗剂
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2002053555A2 (en) * 2001-01-05 2002-07-11 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
AU2002241565A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US20040082606A1 (en) * 2001-12-20 2004-04-29 Khau Vien Van Excitatory amino acid receptor antagonists
WO2003091243A1 (en) 2002-04-26 2003-11-06 Eli Lilly And Company Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
EP2061465B1 (en) 2006-08-23 2013-04-10 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
BRPI0719590A2 (pt) 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
KR20250048143A (ko) 2017-07-31 2025-04-07 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
EP3762414A4 (en) 2018-03-05 2022-01-05 Janssen Pharmaceutica NV TESTS TO DETECT NEURODEGENERATION
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
TW202128162A (zh) 2019-11-08 2021-08-01 加拿大商再諾製藥公司 憂鬱症之治療方法
JP2024508660A (ja) 2021-02-09 2024-02-28 ゼノン・ファーマシューティカルズ・インコーポレイテッド 快感消失の治療に使用するための電位依存性カリウムチャネル開口薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US6242462B1 (en) * 1997-04-07 2001-06-05 Eli Lilly And Company Pharmacological agents
AU5591900A (en) * 1999-07-06 2001-01-22 Eli Lilly And Company Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid

Also Published As

Publication number Publication date
AR029373A1 (es) 2003-06-25
EA200200132A1 (ru) 2002-06-27
NO20016246L (no) 2002-03-04
CA2378613C (en) 2007-10-02
US6855823B2 (en) 2005-02-15
HRP20020013A2 (en) 2003-08-31
US6759418B2 (en) 2004-07-06
HUP0202253A3 (en) 2003-12-29
DE60032905T2 (de) 2007-10-18
DZ3209A1 (fr) 2001-01-11
IL146697A0 (en) 2002-07-25
JP2003503449A (ja) 2003-01-28
HK1047036A1 (zh) 2003-02-07
KR20020024300A (ko) 2002-03-29
EP1200073B1 (en) 2007-01-10
CN1359289A (zh) 2002-07-17
US6566370B1 (en) 2003-05-20
WO2001001972A3 (en) 2001-12-06
PT1200073E (pt) 2007-03-30
DE60032905D1 (de) 2007-02-22
BR0012175A (pt) 2002-03-05
MXPA01012726A (es) 2002-07-02
JP4619595B2 (ja) 2011-01-26
US20040192722A1 (en) 2004-09-30
WO2001001972A2 (en) 2001-01-11
HUP0202253A2 (hu) 2002-11-28
EP1200073A2 (en) 2002-05-02
AU5873200A (en) 2001-01-22
US20050159445A1 (en) 2005-07-21
PE20010299A1 (es) 2001-03-07
NO20016246D0 (no) 2001-12-19
EA004290B1 (ru) 2004-02-26
DK1200073T3 (da) 2007-05-07
NZ515616A (en) 2004-05-28
ES2278619T3 (es) 2007-08-16
CN1230174C (zh) 2005-12-07
US20030199546A1 (en) 2003-10-23
AU773304B2 (en) 2004-05-20
MY133503A (en) 2007-11-30
CA2378613A1 (en) 2001-01-11
US7157582B2 (en) 2007-01-02
SK112002A3 (en) 2003-05-02
CZ20014488A3 (cs) 2003-01-15

Similar Documents

Publication Publication Date Title
TR200200066T2 (tr) Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
CY1104993T1 (el) 4-(πιπεριδυλ- και πυρρολιδινυλ-αλκυλ-ουρεϊδο)-κινολινες ως ανταγωνιστες του υποδοχεα ουροτασινης ii
ATE300533T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate als urotensin ii rezeptor-antagonisten
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
CY1105060T1 (el) Νεες σουλφαμιδες και η χρηση τους σαν ανταγωνιστικων ληπτων ενδοθηλινης
AU4926301A (en) Lpa receptor agonists and antagonists and methods of use
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
TR200401264T4 (tr) CB1-reseptör-antagonistiyle-sibütramin birleşimi, bunları içeren farmasötik-bileşimler ve obezite tedavisinde kullanımları.
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
TR200101895T2 (tr) Cinsel rahatsızlıkların tedavisi.
TR200003801T2 (tr) Acı hafifletmek için deri üstü kompozisyonlar ve yöntemler
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
ATE293691T1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
ATE355288T1 (de) Verbindungen und therapeutische methoden
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
MXPA04001252A (es) Nuevos heterociclos benzo-fusionados como antagonistas de endotelina.
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
ATE279923T1 (de) Urotensin-ii rezeptorantagonisten
BR0111785A (pt) Composições e métodos para tratamento de candidìase
BR0115364A (pt) Tratamento de disfunção sexual
DE50210037D1 (de) VERWENDUNG VON WIRKSTOFFEN MIT õ-OPIOID-REZEPTOR AGONISTISCHER WIRKUNG UND OPIOID-REZEPTOR ANTAGONISTISCHER WIRKUNG ALS KOMBINATIONSARZNEIMITTEL ZUR KREBSBEHANDLUNG